Humana Inc. (HUM) is a large health insurance company with a market cap of around $30.9 billion, operating in the United States through Insurance and CenterWell segments. Although it is a major player in the Medicare Advantage market, HUM’s stock is currently trading 18.5% below its 52-week high and has declined 17.7% over the past three months. Challenges in its Medicare Advantage business have impacted its performance, with weak Q3 2025 results showing a 22.1% drop in non-GAAP EPS. Despite these challenges, analysts have a “Moderate Buy” rating on HUM with a mean price target of $283.67.

Read more at Barchart: How Is Humana Stock Performance Compared to Other Healthcare Services Stocks?